Sanxin Medical announced that the company plans to raise 24 million yuan in capital through the “Jiangxi Chengtukang Electron Accelerator Irradiation Sterilization Production Line Renovation and Expansion Project” to increase investment in Jiangxi Chengtukang Technology Co., Ltd., a wholly-owned second-tier subsidiary. The capital increase is based on Jiangxi Chengtukang's net assets of RMB 10,418,900 as of June 30, 2026. After the capital increase, the company directly held 69.7291% of its shares and still controls 100% of the total shares. The scope of the consolidated statement remains unchanged; the registered capital of Jiangxi Chengtukang will increase from 5 million yuan to 165175.31 million yuan. This capital increase is only used for the implementation of fund-raising projects. It does not constitute a related transaction or major asset restructuring, and there is no need to submit it to the shareholders' meeting for review.

Sanxin Medical announced that the company plans to raise 24 million yuan in capital through the “Jiangxi Chengtukang Electron Accelerator Irradiation Sterilization Production Line Renovation and Expansion Project” to increase investment in Jiangxi Chengtukang Technology Co., Ltd., a wholly-owned second-tier subsidiary. The capital increase is based on Jiangxi Chengtukang's net assets of RMB 10,418,900 as of June 30, 2026. After the capital increase, the company directly held 69.7291% of its shares and still controls 100% of the total shares. The scope of the consolidated statement remains unchanged; the registered capital of Jiangxi Chengtukang will increase from 5 million yuan to 165175.31 million yuan. This capital increase is only used for the implementation of fund-raising projects. It does not constitute a related transaction or major asset restructuring, and there is no need to submit it to the shareholders' meeting for review.